217 related articles for article (PubMed ID: 21601640)
1. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.
Ahmad I; Labbé AC; Chagnon M; Busque L; Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Roy J
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1673-8. PubMed ID: 21601640
[TBL] [Abstract][Full Text] [Related]
2. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
5. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
Kim DH; Popradi G; Xu W; Gupta V; Kuruvilla J; Wright J; Messner HA; Lipton JH
Biol Blood Marrow Transplant; 2009 Apr; 15(4):471-82. PubMed ID: 19285635
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
10. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
[TBL] [Abstract][Full Text] [Related]
11. Eosinophilia predicts better overall survival after acute graft-versus-host-disease.
Imahashi N; Miyamura K; Seto A; Watanabe K; Yanagisawa M; Nishiwaki S; Shinba M; Yasuda T; Kuwatsuka Y; Terakura S; Kodera Y
Bone Marrow Transplant; 2010 Feb; 45(2):371-7. PubMed ID: 19525984
[TBL] [Abstract][Full Text] [Related]
12. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.
Solano C; Martinez C; Brunet S; Tomás JF; Urbano-Ispizua A; Zuazu J; Ojeda E; Bargay J; Moraleda JM; Bailen A; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Dec; 22(12):1129-35. PubMed ID: 9894714
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
15. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation.
Mortensen KB; Gerds TA; Bjerrum OW; Lindmark A; Sengeløv H; Andersen CL
Leuk Res; 2014 Mar; 38(3):334-9. PubMed ID: 24439053
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
19. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
20. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
